Vari F, Hart D N J
Mater Medical Research Institute, Queensland, South Brisbane, Australia.
Cytotherapy. 2004;6(2):111-21. doi: 10.1080/14653240410005230.
Understanding the biology of the DC and its pivotal role in immune response initiation and regulation has enabled new effective anti-cancer therapies to be developed for treatment of a wide range of tumor types. Many studies on DC-based cancer vaccine development have focused on the development of methods that can effectively deliver tumor Ags to DCs. Numerous methods have been developed or evaluated for the delivery of defined and undefined tumor Ags to DCs for processing and presentation to T lymphocytes. This review provides a brief summary of these methods, the techniques that are used in each, how they have -- or could -- be applied clinically, as well as the advantages and disadvantages of each method.
了解树突状细胞(DC)的生物学特性及其在免疫反应启动和调节中的关键作用,使得人们能够开发出新的有效抗癌疗法,用于治疗多种肿瘤类型。许多基于DC的癌症疫苗开发研究都集中在开发能够有效将肿瘤抗原递送至DC的方法上。已经开发或评估了多种方法,用于将确定的和未确定的肿瘤抗原递送至DC,以便其处理并呈递给T淋巴细胞。本综述简要总结了这些方法、每种方法所使用的技术、它们在临床上的应用方式或可能的应用方式,以及每种方法的优缺点。